Related Experiment Videos
Topoisomerase I inhibitors: review and update
1Division of Medical Oncology, University of Texas Health Science Center at San Antonio, USA.
Abstract:
This review presents a summary of preclinical and clinical data on the topoisomerase I (topo I) inhibitors that are under clinical development. To date, all of the topo I inhibitors that have been clinically evaluated are analogues of camptothecin, an extract of the Chinese tree Camptotheca acuminata. The therapeutic development of camptothecin was initially limited by its poor solubility and unpredictable toxicity. More recently, a number of water-soluble camptothecin analogues have undergone extensive evaluation and have demonstrated significant clinical activity. These include irinotecan (CPT-II), topotecan, and 9-aminocamptothecin (9-AC). Preliminary data are also reviewed on other camptothecin analogues (GG-211 and DX-8951f), on oral formulations, and on non-camptothecin topoisomerase I inhibitors. The topoisomerase I inhibitors have already demonstrated a broad spectrum of antitumour activity, most probably due to their unique mechanism of action and lack of clinical cross-resistance with existing antineoplastic compounds. The challenge for the next five years is to identify ways to integrate the topo I inhibitors into multidrug and multimodality therapies to achieve optimal antitumour effect, while keeping the side effects of these therapies manageable.
Insights
Topoisomerase I (topo I) inhibitors, primarily camptothecin analogues like irinotecan and topotecan, show broad anticancer activity. Future research focuses on integrating these agents into combination therapies for better outcomes.
Area of Science:
- Oncology
- Pharmacology
- Medicinal Chemistry
Background:
- Topoisomerase I (topo I) inhibitors are a class of anticancer agents.
- Camptothecin, derived from Camptotheca acuminata, was the first topo I inhibitor.
- Early camptothecin development was hindered by poor solubility and toxicity.
Purpose of the Study:
- To review preclinical and clinical data of developing topo I inhibitors.
- To summarize the efficacy and challenges of camptothecin analogues.
- To explore future directions for topo I inhibitor therapies.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of data on camptothecin analogues and novel inhibitors.
- Evaluation of therapeutic strategies and challenges.
Main Results:
- Water-soluble camptothecin analogues, including irinotecan, topotecan, and 9-aminocamptothecin, exhibit significant clinical activity.
- Newer analogues (GG-211, DX-8951f), oral formulations, and non-camptothecin inhibitors are under investigation.
- Topo I inhibitors demonstrate broad-spectrum antitumor activity and lack cross-resistance with existing drugs.
Conclusions:
- Topoisomerase I inhibitors offer a promising therapeutic approach in oncology.
- Optimizing their use in combination therapies is crucial for maximizing antitumor effects.
- Managing side effects remains a key consideration for successful integration into treatment regimens.